|3.||Postoperative Nausea and Vomiting (PONV)
|1.||Shupak, Avi: 10 articles (01/2014 - 01/2003)|
|2.||Tal, Dror: 8 articles (01/2014 - 08/2005)|
|3.||Li, Min: 6 articles (03/2014 - 07/2004)|
|4.||Nachum, Zohar: 6 articles (07/2012 - 01/2003)|
|5.||Navari, Rudolph M: 6 articles (07/2010 - 07/2003)|
|6.||Bar, Ronen: 5 articles (07/2012 - 11/2005)|
|7.||Gil, Amnon: 5 articles (07/2012 - 08/2005)|
|8.||Uno, A: 5 articles (09/2001 - 03/2000)|
|9.||Jiang, Zheng-Lin: 4 articles (01/2015 - 01/2005)|
|10.||Marcus, Dawn A: 4 articles (02/2011 - 12/2005)|
|1.||Scopolamine (Hyoscine)FDA Link
08/01/2005 - "Scopolamine is highly effective for the treatment of seasickness. "
01/01/1996 - "A strong correlation was found between motion sickness and emetic sequelae after surgery, and patients with a history of motion sickness benefited most from hyoscine."
08/01/2005 - "Nevertheless, transdermal therapeutic system (TTS) scopolamine, despite high compliance on the part of persons treated by the drug, fails to provide protection against seasickness in 26-38% of patients. "
01/01/1987 - "We conclude that transdermal scopolamine's efficacy against seasickness during a 3-day cruise was not associated with significant side effects and, therefore, we find the drug suitable for long-term use by sailing crews."
01/01/1992 - "We conclude that buccal scopolamine is more effective than a placebo in treating ongoing motion sickness."
|2.||Dimenhydrinate (DMH)FDA LinkGeneric
09/01/1986 - "Due to its galenic properties, SCOTTS is effective over a 72-h period and therefore is useful in the prevention of motion sickness during long-distance flights, where it is superior to dimenhydrinate."
11/01/1984 - "TTSS afforded 61.67% protection against motion sickness at sea, compared to 48.88% protection with dimenhydrinate."
01/01/2002 - "A randomised, placebo-controlled study comparing two formulations of dimenhydrinate with respect to efficacy in motion sickness and sedation."
02/01/2011 - "I recall reading that the motion-sickness drug Dramamine could help if you're having a heart attack. "
01/01/2006 - "The investigation has demonstrated that [see text] has rather strong anti-sea-sickness effect, is comparable with dimenhydrinate effectiveness and prevents the development of disorders in sensory-and-motor and cognitive functions during the influence of static-and- kinetic loads. "
07/01/1994 - "In conclusion, cinnarizine 50 mg was found to be effective in the prevention of seasickness in rough seas."
06/01/1994 - "Seasickness symptoms were improved in 69% of the subjects by 50 mg cinnarizine versus 35% and 31% in the groups receiving 25 mg cinnarizine and placebo (p < 0.05 and p < 0.01, respectively). "
07/01/1994 - "In a double-blind, placebo-controlled study, we evaluated the effect of two different doses of cinnarizine in the prevention of seasickness in very rough seas. "
06/01/1994 - "Cinnarizine was evaluated for the prevention of seasickness in a laboratory and sea study. "
06/01/1994 - "Cinnarizine in the prophylaxis of seasickness: laboratory vestibular evaluation and sea study."
|4.||Granisetron (Kytril)FDA LinkGeneric
01/01/1999 - "In conclusion, prophylactic antiemetic therapy with granisetron is effective for preventing postoperative emesis in children with a history of motion sickness as well as in those without it."
02/01/1996 - "These results suggest that preoperative prophylactic administration of granisetron is effective and safe for preventing postoperative nausea and vomiting in patients with motion sickness as well as in patients without it."
12/01/2012 - "Retraction note to: Antiemetic effects of granisetron on postoperative nausea and vomiting in patients with and without motion sickness. "
01/01/2000 - "Prevention of postoperative vomiting with granisetron in paediatric patients with and without a history of motion sickness."
01/01/1999 - "A complete response, defined as no vomiting, no retching and no need for another rescue medication, during the first 24 h after anaesthesia was 77% and 13% in patients with a history of motion sickness who had received granisetron or placebo, respectively; the corresponding incidence was 83% and 40% in those without it (P < 0.05; chi 2 test with Yates' continuity correction). "
|5.||Promethazine (Promet)FDA LinkGeneric
10/01/2000 - "Autogenic-feedback training exercise is superior to promethazine for control of motion sickness symptoms."
10/01/2000 - "An earlier study tested the effects of promethazine on cognitive and psychomotor performance and motion sickness tolerance in a rotating chair. "
01/01/2015 - "The results of experimental clinical testing of the antinaupathia action of as new compounds, so motion sickness medications (promethazine, ikaron-1 etc.) are presented. "
01/01/2008 - "Development of a melting tablet containing promethazine HCl against motion sickness."
03/01/2007 - "Microcapsule-gel formulation of promethazine HCl for controlled nasal delivery: a motion sickness medication."
|6.||Diphenhydramine (Benadryl)FDA LinkGeneric
01/01/1999 - "The modulatory effect of diphenhydramine on PVN neuron activity may explain in part this drug's efficacy in treating motion sickness."
06/01/2003 - "This study indicates that the pharmaceutical formulation employed provided sustained plasma concentrations of diphenhydramine, presumably sufficient to support its clinical efficacy towards motion sickness owing to the almost complete (> 95%) release by the formulation of the active principle. "
01/01/1999 - "The mode of action of diphenhydramine in treating motion sickness is unknown. "
05/01/1992 - "The failure of diphenhydramine to prevent motion sickness was unexpected. "
05/01/1992 - "In contrast, diphenhydramine failed to prevent motion sickness in any of the tested doses. "
10/01/2003 - "The authors' objectives were: 1) to determine the incidence of motion sickness during ambulance transport on a mountainous route in healthy volunteers, and 2) to determine if droperidol alleviated the signs and symptoms of motion sickness in those volunteers who developed it. "
11/01/1996 - "Periovulatory period (menstrual dates 11-24) and history of motion sickness were predictors for R&V. During 2-24hr, both the percentage of patients needing droperidol and the mean number of doses were lower in the perimenstrual group (menstrual dates 25-10) than in the periovulatory group 27 vs 51% (P < 0.05) and 0.2 vs 0.7 (P < 0.01), respectively. "
10/01/2003 - "Those who developed motion sickness rated their nausea on a 100-mm visual analog scale (VAS) and were randomized to receive placebo (saline) or 2.5 mg droperidol intravenously. "
08/01/1988 - "Since transdermal scopolamine (TS) seems effective against seasickness, we compared its antiemetic effect with intravenous droperidol (DHBP), our routine antidote for postoperative emesis. "
02/01/1996 - "No reduction in PONV was observed in patients with a history of motion sickness, whereas in patients without a history of motion sickness, ondansetron reduced both the proportion of patients suffering from PONV from 53% to 20% (P < 0.05) and of those needing droperidol from 53% to 17% (P < 0.05)."
|8.||Metoclopramide (Reglan)FDA LinkGeneric
07/01/1973 - "An evaluation of metoclopramide as an anti-emetic in seasickness."
01/01/2014 - "Metoclopramide is commonly used to treat vomiting caused by seasickness and acute gastroenteritis on cruise ships and serious adverse effects have not been reported from use at sea. "
02/01/1987 - "Although metoclopramide is an effective antiemetic agent that enhances gastric emptying and prevents cancer chemotherapy-induced emesis, we were unable to demonstrate any significant (p less than 0.05) effects of this drug on motion sickness."
07/01/2011 - "This is an evaluation of the efficacy of metoclopramide (MTCP) or diphenhydramine (DPH) to relieve symptoms of motion sickness in patients being transported via ambulance in a mountainous setting. "
07/01/2011 - "Motion sickness: comparison of metoclopramide and diphenhydramine to placebo."
|9.||Acetylcholine (Acetylcholine Chloride)FDA Link
11/01/2009 - "A new hypothesis is herein presented which posits that acetylcholine (ACh) acts as a neurohumeral agent to bring about the symptoms associated with motion sickness. "
11/01/2009 - "Motion sickness may be caused by a neurohumoral action of acetylcholine."
09/01/1989 - "These results suggested that centrally acting acetylcholine play an important role in suppressing habituation of motion sickness. "
09/01/1987 - "The drugs effective in preventing motion sickness are divided into those with central acetylcholine blocking activity and those which enhance norepinephrine activity. "
09/01/1987 - "The balance between the acetylcholine and norepinephrine activity in the CNS appears to be responsible for motion sickness."
09/28/2001 - "Recent studies, which have shown an increase of plasma vasopressin (VP) in experimental motion sickness and the efficacy of VP antagonists for motion sickness, suggest an important role of VP in the development of vestibulo-autonomic responses. "
03/01/2008 - "This study was to investigate the effect of gastric electrical stimulation (GES) with short pulses, long pulses, short-pulse trains or long-pulse trains on gastric dysrhythmia and motion-sickness signs induced by vasopressin. "
04/01/2005 - "The aim of this study was to investigate the effects of two-channel gastric electrical stimulation (GES) on delayed gastric emptying, gastric dysrhythmias, and motion sickness-like symptoms induced by vasopressin. "
01/01/2005 - "This study was designed to verify the assumption that plasma vasopressin plays a role in motion sickness. "
05/01/2004 - "The aim of this study was to investigate the effect of intestinal electrical stimulation on small intestinal dysrhythmia and motion sickness-like symptoms induced by vasopressin. "
|1.||Drug Therapy (Chemotherapy)
02/01/1997 - "Age, gender, history of motion sickness, aggressiveness of the chemotherapy, PNV severity, number of chemotherapy treatments, number, type, and efficacy of self-reported coping strategies, and expectations of severity of postchemotherapy symptoms failed to differentiate the ANV and NANV groups. "
07/01/2013 - "The emetogenicity of the chemotherapeutic agents, repeated chemotherapy cycles, and patient characteristics (female gender, younger age, low alcohol consumption, history of motion sickness) are the major risk factors for CINV. "
07/01/2010 - "The emetogenicity of the chemotherapeutic agents, repeated chemotherapy cycles and patient characteristics (e.g., female gender, younger age, low alcohol consumption and history of motion sickness) are the major risk factors for CINV. "
12/01/2009 - "The emetogenicity of the chemotherapeutic agents, repeated chemotherapy cycles and patient characteristics (female gender, younger age, low alcohol consumption, history of motion sickness) are the major risk factors for CINV. "
01/01/2009 - "The emetogenicity of the chemotherapeutic agents, repeated chemotherapy cycles, and patient characteristics (female gender, younger age, low alcohol consumption, history of motion sickness) are the major risk factors for CINV. "
08/01/1991 - "In spite of previous reports to the contrary, acupressure provided no protection against motion sickness for either high or low susceptible subjects."
03/01/2004 - "Efficacy of acupressure and acustimulation bands for the prevention of motion sickness."
01/01/2003 - "Are acupressure wrist bands helpful for motion sickness?"
03/01/2004 - "The purpose of this study was to examine whether acupressure and acustimulation prevent motion sickness, taking into consideration whether or not the acupressure and acustimulation are administered properly. "
08/01/2005 - "60 women with high and low susceptibilities for motion sickness participated in a randomized and double-blind study with an active P6 acupressure, placebo acupressure, and a control group (n = 20 in each group). "
01/01/1999 - "This prospective, randomized, double-blind, placebo-controlled study was undertaken to assess the efficacy of granisetron, a selective 5-hydroxytryptamine type 3 receptor antagonist, for preventing postoperative vomiting after tonsillectomy in 120 children with (n = 60) and without (n = 60) a history of motion sickness. "
03/01/2001 - "Prophylactic therapy with granisetron is superior to droperidol or metoclopramide for the prevention of POV after tonsillectomy in children with a history of motion sickness."
03/01/2001 - "This study was undertaken to compare the efficacy of granisetron, droperidol, and metoclopramide for the prevention of POV after tonsillectomy in children with a history of motion sickness. "
03/01/2001 - "Comparison of granisetron, droperidol, and metoclopramide for prevention of postoperative vomiting in children with a history of motion sickness undergoing tonsillectomy."
|4.||Complementary Therapies (Alternative Medicine)
12/01/2007 - "The National Center for Complementary and Alternative Medicine (NCCAM) has evaluated the results of the available studies, rating the reports from "suggestive" (for short-term use of Ginger for safe relief from pregnancy related nausea and vomiting), to "mixed" (when used for nausea caused by motion sickness, chemotherapy, or surgery), and to "unclear" for treating rheumatoid arthritis, osteoarthritis, or joint and muscle pain). "
04/01/2007 - "Intranasal SCOP in situ gel at a dose of 100 microg/kg decreased symptoms of motion sickness significantly in comparison with subcutaneous and oral administration (P<0.01). "
01/01/2008 - "Here we demonstrate that the reduction in T(VOR) produced by oral administration of 20 mg of baclofen causes a significant reduction in motion sickness susceptibility, tested with roll while rotating (RWR). "
11/01/1992 - "Significant positive correlations were found between susceptibility to motion sickness and to emesis induced by intraperitoneal administration of apomorphine and by oral administration of copper sulfate. "